A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia
详细信息 查看全文
- 作者：Isabel Gonzá ; lez-Gascó ; n y Marí ; n ; Marí ; a Herná ; ndez-Sá ; nchez ; Ana-Eugenia Rodrí ; guez-Vicente ; Carmen Sanzo ; Anna Aventí ; n ; Anna Puiggros ; Rosa Collado ; Cecilia Heras ; Carolina Muñ ; oz ; Julio Delgado ; Margarita Ortega ; Marí ; a-Teresa Gonzá ; lez ; Isabel Marugá ; n ; Ignacio de la Fuente ; Isabel Recio ; Francesc Bosch ; Blanca Espinet ; Marcos Gonzá ; lez ; Jesú ; s-Marí ; a Herná ; ndez-Rivas ; José ; -Á ; ngel Herná ; ndez ; On behalf of Grupo Españ ; ol de Leucemia Linfá ; tica Cró ; nica (GELLC) and Grupo Cooperativo Españ ; ol de Citogené ; tica Hematoló ; gica (GCECGH)
- 刊名：Hematological Oncology
- 出版年：2016
- 出版时间：June 2016
- 年：2016
- 卷：34
- 期：2
- 页码：84-92
- 全文大小：267K
- ISSN：1099-1069
文摘
The prognosis of chronic lymphocytic leukemia (CLL) patients displaying trisomy 12 (+12) remains unclear. In this study, we analyzed the influence of the proportion of cells with +12, and other clinical and biologic factors, in time to first therapy (TTFT) and overall survival (OS), in 289 patients diagnosed with CLL carrying +12. Median OS was 129 months. One hundred seventy-four patients (60.2%) presented +12 in <60% of cells. TTFT and OS for this subgroup were longer than for the subgroup with +12 in ≥60% of cells, with a median TTFT of 49 months (CI95%, 39–58) vs 30 months (CI95%, 22–38) (P = 0.001); and a median OS of 159 months (CI95%, 119–182), vs 96 months (CI95%, 58–134) (P = 0.015). Other factors associated with a shorter TTFT were: Binet stage, B symptoms, lymphadenopathy, splenomegaly, high lymphocyte count, 11q-, high β2microglobulin, and high LDH. In the multivariate analysis, clinical stage, +12 in ≥60% of cells, high lymphocyte count, B symptoms, and 11q- in addition, resulted of significance in predicting shorter TTFT. Significant variables for OS were: Binet stage, lymphadenopathy, splenomegaly, high LDH, high β2microglobulin, 11q-, and CD38. In the multivariate analysis, only Binet stage, 11q-, and high β2microglobulin significantly predicted shorter OS. CLL with +12 entails a heterogeneous group with intermediate prognosis. However, a high proportion of cells carrying +12 separates a subgroup of patients with poor outcome. Copyright